Merck (MRK) ’s stock surged by 41% in the last six months, driven not only by a modest revenue increase but also by a ...

Merck & Co., Inc. (NYSE:MRK) is among the most profitable healthcare stocks to buy. On January 21, TheFly reported that BofA ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the ...

On January 27, Cantor Fitzgerald boosted its price target on Merck & Co., Inc. (NYSE:MRK) to $116 from $83 but kept its ...

The drugmaker had recently been in discussions to acquire RevMed in a deal that could have valued the cancer-drug biotech at ...

The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...

The company’s previous CCO was Cristal Downing, who joined Insulet as chief corporate affairs officer late last year.

The pharmaceutical giant had been in talks to buy the cancer drug developer in a transaction that could have valued ...

By Arasu Kannagi Basil Jan 28 (Reuters) - Eikon ‍Therapeutics, headed by Merck veteran Roger Perlmutter, is targeting a valuation of up to $908.2 million in its initial public offering in the United ...

A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin ...

Guardant Health (GH) is back in focus after the FDA approved its Guardant360 CDx liquid biopsy as a companion diagnostic for BRAF V600E-mutant metastatic colorectal cancer and the company announced a ...

Jan 25 (Reuters) - Merck is no longer in discussions to buy cancer drug developer Revolution Medicines, the Wall Street ...